DE69923470D1 - Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion - Google Patents

Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion

Info

Publication number
DE69923470D1
DE69923470D1 DE69923470T DE69923470T DE69923470D1 DE 69923470 D1 DE69923470 D1 DE 69923470D1 DE 69923470 T DE69923470 T DE 69923470T DE 69923470 T DE69923470 T DE 69923470T DE 69923470 D1 DE69923470 D1 DE 69923470D1
Authority
DE
Germany
Prior art keywords
virus
hepatitis
measles
masonic
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69923470T
Other languages
English (en)
Other versions
DE69923470T2 (de
Inventor
Pengfu Wang
Jingye Liu
Guangpu Li
Yifan Nan
Meihua Wang
Wei Wang
Jianjun Guo
Baosheng Xie
Zongming Song
Cuibo Qu
Lisha Liu
Jinfeng Huang
Zongju Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changchun Institute of Biological Products
Original Assignee
Changchun Institute of Biological Products
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changchun Institute of Biological Products filed Critical Changchun Institute of Biological Products
Priority claimed from PCT/CN1999/000162 external-priority patent/WO2000029018A1/zh
Publication of DE69923470D1 publication Critical patent/DE69923470D1/de
Application granted granted Critical
Publication of DE69923470T2 publication Critical patent/DE69923470T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18461—Methods of inactivation or attenuation
    • C12N2760/18464—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32461—Methods of inactivation or attenuation
    • C12N2770/32464—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE1999623470 1998-11-12 1999-10-13 Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion Expired - Fee Related DE69923470T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN98124548A CN1062770C (zh) 1998-11-12 1998-11-12 甲肝-麻疹二联疫苗及其生产方法
CN98124548 1998-11-12
PCT/CN1999/000162 WO2000029018A1 (fr) 1998-11-12 1999-10-13 Vaccin combine contre l'hepatite a et la rougeole et son procede de preparation

Publications (2)

Publication Number Publication Date
DE69923470D1 true DE69923470D1 (de) 2005-03-03
DE69923470T2 DE69923470T2 (de) 2006-03-30

Family

ID=5228699

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1999623470 Expired - Fee Related DE69923470T2 (de) 1998-11-12 1999-10-13 Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion

Country Status (7)

Country Link
US (1) US6562350B1 (de)
EP (1) EP1129723B1 (de)
KR (1) KR20010101005A (de)
CN (1) CN1062770C (de)
AT (1) ATE287726T1 (de)
AU (1) AU6323599A (de)
DE (1) DE69923470T2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
US8124397B2 (en) * 2005-08-08 2012-02-28 Oregon Health & Science University Inactivating pathogens with oxidizing agents for vaccine production
RU2541784C2 (ru) * 2006-11-07 2015-02-20 Санофи Пастер Байолоджикс Ко. Лиофилизированная композиция для индукции иммунного ответа на флавивирус, композиция и способ для ее получения
CA2720570C (en) 2007-04-06 2022-10-04 Inviragen, Inc. Methods and compositions for live, attenuated dengue viruses
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
CN102210858B (zh) * 2011-05-18 2013-05-08 北京科兴生物制品有限公司 一种肠道病毒71型与甲型肝炎联合疫苗
CN102343087A (zh) * 2011-10-21 2012-02-08 长春祈健生物制品有限公司 麻疹长-47株制备二倍体细胞减毒活疫苗及制备工艺
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
EP3103474A1 (de) * 2015-06-12 2016-12-14 Institut Pasteur Lebendes rekombinantes masern-m2-virus und dessen verwendung bei auslösung von immunität gegen influenzaviren
CN108135995A (zh) * 2015-09-30 2018-06-08 万能药生物有限公司 稳定的活的减毒重组登革疫苗
CN113218723A (zh) * 2021-03-16 2021-08-06 吴敏 一种用于显微镜观察的组合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1792356C2 (de) * 1968-08-23 1983-03-03 Behringwerke Ag, 3550 Marburg Staupe-Kombinationsvaccinen und Verfahren zu ihrer Herstellung
FR2633518B1 (fr) * 1988-06-30 1991-03-22 Merieux Inst Procede de stabilisation des vaccins et associations de vaccins a virus attenues conserves sous forme lyophilisee, et compositions obtenues
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
CN1029239C (zh) * 1992-12-29 1995-07-05 卫生部长春生物制品研究所 甲型肝炎疫苗的生产方法
AU725231B2 (en) * 1996-12-20 2000-10-12 Merck & Co., Inc. Stabilisers for lyophilised vaccines

Also Published As

Publication number Publication date
CN1217212A (zh) 1999-05-26
ATE287726T1 (de) 2005-02-15
US6562350B1 (en) 2003-05-13
KR20010101005A (ko) 2001-11-14
DE69923470T2 (de) 2006-03-30
EP1129723A4 (de) 2002-10-24
AU6323599A (en) 2000-06-05
EP1129723B1 (de) 2005-01-26
CN1062770C (zh) 2001-03-07
EP1129723A1 (de) 2001-09-05

Similar Documents

Publication Publication Date Title
DE69923470D1 (de) Kombinationsimpfstoff gegen hav und masernvirus und verfahren zu seiner produktion
DE60033284D1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
RS100504A (en) Hepatitis c virus inhibitors
WO2005054430A3 (en) Hepatitis c virus inhibitors
DE50214416D1 (de) Vermehrung von viren in zellkultur
HK1080507A1 (en) Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
DK0935660T3 (da) Infektiöse kloner af RNA-virusser og vacciner og deraf afledte diagnostiske assays
PT891420E (pt) Processos para a replicacao dos virus influenza numa cultura celular e os virus influenza que se podem obter atraves do processo
CY1110964T1 (el) Μεθοδος παραγωγης εμβολιων μεγαλης κλιμακας
IS8448A (is) Lifrarbólgu C-veirutálmar
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
WO2003053332A3 (en) Composition and method for treating viral infection
BR0114884A (pt) Compostos calcilìticos
ATE105293T1 (de) Phosphortrilactame und verfahren zu deren herstellung.
JPS57126423A (en) Preparation of mixed viral live vaccine
NL7709998A (en) Foetal canine lung diploid cell line - for virus cultures esp. for rabies vaccine prodn.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee